Research and development collaborations

Zymeworks·Products & Services·13 segments·Rolls up to Total Revenue

Breakdown

Segment	Q2 '24	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26
Royalties	$0	$0	$100K	$202K	$550K	$831K	$898K	$1.33M
Development support payments	$1.11M	$764K	—	$4.49M	$475K	$352K	$296K	$392K
Drug supply for ongoing studies	$3.98M	$5.27M	$3.76M	$2.96M	$1.84M	$970K	$780K	$345K
Other drug supply	$5.75M	$6.03M	$2.11M	$2.15M	$7K	$71K	$0	$117K
Milestone revenue	$8M	$2.5M	$25M	$14M	$20M	$25M	—	$0
Commercial and Development Milestones	$0	$0	$0	$0	$0	$0	$0	—
Research, Development and Commercial Milestones	$0	$0	$0	$0	$0	$0	$0	—
Technology Access Fee	$1.5M	$1.5M	$1.5M	$1.5M	$1.5M	$1.5M	$1.5M	—
Research Milestone	—	—	—	$8.75M	$8.75M	$8.75M	$8.75M	—
Commercial Sales Milestones	—	—	—	$216.75M	$216.75M	$216.75M	$216.75M	—
Total	$19.24M	$16M	$31.03M	$27.11M	$48.73M	$27.61M	$2.52M	$2.41M

Commercial and Development Milestones, Research, Development and Commercial Milestones, Technology Access Fee, Research Milestone, Commercial Sales Milestones, Bispecific Antibodies, Metastatic Castration-Resistant Prostate Cancer are derived from annual filings.

Segments

Development support paymentsView metric

Drug supply for ongoing studiesView metric

Other drug supplyView metric

RoyaltiesView metric

Milestone revenueView metric

Recognition of deferred revenueView metric

Commercial and Development MilestonesView metric

Research, Development and Commercial MilestonesView metric

Technology Access FeeView metric

Research MilestoneView metric

Commercial Sales MilestonesView metric

Bispecific AntibodiesView metric

Metastatic Castration-Resistant Prostate CancerView metric